MOLECULIN BIOTECH, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On September 9, 2020, Moleculin Biotech, Inc. (the "Company") issued a press release announcing the successful completion of a pre-IND meeting with the FDA.

A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits.

Exhibit No. Description



  99.1     Press Release dated September 9, 2020
104      Cover Page Interactive Data File (formatted as Inline XBRL and contained

in Exhibit 101)

© Edgar Online, source Glimpses